Revenue Update on ABIOMED(NASDAQ:ABMD)

ABIOMED(NASDAQ:ABMD) announced the earnings results for Fiscal Year 2017 and Q1. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $103.00M. Analysts estimated a revenue of $97.23M. Earnings per share were $0.29. Analysts had estimated an EPS of $0.23.

In a different note, On May 4, 2016, Leerink Swann said it Maintains its rating on ABIOMED. In the research note, the firm Raises the price-target to $120.00 per share. The shares have been rated ‘Outperform’ by the firm.

ABIOMED (ABMD) made into the market gainers list on Thursdays trading session with the shares advancing 2.39% or 2.83 points. Due to strong positive momentum, the stock ended at $121.41, which is also near the day’s high of $121.57. The stock began the session at $118.73 and the volume stood at 5,49,692 shares. The 52-week high of the shares is $121.57 and the 52 week low is $67.805. The company has a current market capitalization of $5,188 M and it has 4,27,35,136 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jul 1, 2016, Michael G Howley (VP, Global Sales & Marketing) sold 10,000 shares at $106.58 per share price.Also, On Jun 9, 2016, Andrew J Greenfield (VP Healthcare Solutions) sold 9,000 shares at $104.16 per share price.On May 25, 2016, David M Weber (Chief Operating Officer) sold 4,342 shares at $97.21 per share price, according to the Form-4 filing with the securities and exchange commission.

Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

ABIOMED - Is it time to Sell?

Top Brokerage Firms are advising their investors on ABIOMED. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.